thiophenes has been researched along with Carcinoma, Transitional Cell in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (25.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bender, S; Boix, O; Cassier, PA; Cathomas, R; Cho, BC; Ellinghaus, P; Gajate, P; Grevel, J; Joerger, M; Navarro, A; Nogai, H; Nogova, L; Ocker, M; Park, SH; Penel, N; Rajagopalan, P; Richly, H; Sayehli, CM; Schostak, M; Schuler, M; Soo, RA; Tai, D | 1 |
| Hubert, P; Loriot, Y; Selmani, Z; Thiery-Vuillemin, A | 1 |
| Cinatl, J; Hoffmann, MJ; Isono, M; Michaelis, M; Niegisch, G; Pinkerneil, M; Sato, A; Schulz, WA | 1 |
| Biondo, F; Caramia, G; Gebbia, N; Pavone-Macaluso, M; Rausa, L; Rizzo, FP | 1 |
1 trial(s) available for thiophenes and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
Rogaratinib in patients with advanced cancers selected by FGFR mRNA expression: a phase 1 dose-escalation and dose-expansion study.
Topics: Acute Kidney Injury; Aged; Anorexia; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Transitional Cell; Diarrhea; Fatigue; Female; Humans; Hyperphosphatemia; Hypoglycemia; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Piperazines; Pyrroles; Receptor, Fibroblast Growth Factor, Type 1; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Receptors, Fibroblast Growth Factor; RNA, Messenger; Squamous Cell Carcinoma of Head and Neck; Thiophenes; Vomiting | 2019 |
3 other study(ies) available for thiophenes and Carcinoma, Transitional Cell
| Article | Year |
|---|---|
FGFR alterations in urothelial carcinoma: Picking the right target.
Topics: Carcinoma, Transitional Cell; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Gene Fusion; Humans; Molecular Targeted Therapy; Morpholines; Mutation; Phenylurea Compounds; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Pyrroles; Quinoxalines; Receptor, Fibroblast Growth Factor, Type 2; Receptor, Fibroblast Growth Factor, Type 3; Thiophenes; Urinary Bladder Neoplasms | 2021 |
Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.
Topics: Antimetabolites, Antineoplastic; Carcinoma, Transitional Cell; Caspases; Cell Cycle; Cell Line, Tumor; Cell Survival; Checkpoint Kinase 1; Checkpoint Kinase 2; Deoxycytidine; DNA Damage; Drug Screening Assays, Antitumor; Drug Synergism; Gemcitabine; Gene Expression Regulation, Neoplastic; Humans; Poly(ADP-ribose) Polymerases; Protein Kinase Inhibitors; RNA, Small Interfering; Thiophenes; Urea; Urinary Bladder Neoplasms | 2017 |
Experimental techniques for testing the sensitivity of bladder tumours to antineoplastic drugs.
Topics: Administration, Topical; Animals; Antineoplastic Agents; Carcinoma, Transitional Cell; Cell Nucleus; Cricetinae; Cytotoxicity Tests, Immunologic; Daunorubicin; Demecolcine; DNA, Neoplasm; Doxorubicin; Drug Resistance; Fluorescence; Glycosides; Humans; Melphalan; Microscopy, Fluorescence; Neoplasm Transplantation; Oxidoreductases; Podophyllotoxin; Protein Biosynthesis; Thiophenes; Thiotepa; Transplantation, Heterologous; Urinary Bladder Neoplasms | 1973 |